In this study, we have compared the abilities of orexin-A and orexin-B and variants of orexin-A to activate different Ca 2ϩ responses (influx and release) in human OX 1 and OX 2 receptorexpressing Chinese hamster ovary cells. Responses mediated by activation of both receptor subtypes with either orexin-A or -B were primarily dependent on extracellular Ca 2ϩ , suggesting similar activation of Ca 2ϩ influx as we have previously shown for orexin-A and OX 1 receptors. Amino acid-wise truncation of orexin-A reduced its ability to activate OX 1 and OX 2 receptors, but the response mediated by the OX 2 receptor was more resistant to truncation than the response mediated by the OX 1 receptor. We also performed a sequential replacement of amino acids 14 to 26 with alanine in the truncated orexin-A variant orexin-A 14 -33 . Replacement of the same amino acids produced a fall in the potency for each receptor subtype, but the reduction was less prominent for the OX 2 receptor. The most marked reduction was produced by the replacement of Leu20, Asp25, and His26 with alanine. Interestingly, extracellular Ca 2ϩ dependence of responses to some of the mutated peptides was different from those of orexin-A and -B. The mutagenesis also suggests that although the determinants required from orexin-A for binding to and activation of the receptor are highly conserved between the orexin receptor subtypes, the OX 2 receptor requires fewer determinants. This might in part explain why orexin-B has the affinity and potency equal to orexin-A for this subtype, although it has 10-to 100-fold lower affinity and potency for the OX 1 receptor.
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Recently, two novel hypothalamic peptides were isolated and subsequently named orexin-A and orexin-B (Sakurai et al., 1998) or hypocretin-1 and hypocretin-2 (de Lecea et al., 1998) . Despite some initial confusion, orexin-A should now be considered identical to hypocretin-1 and orexin-B to hypocretin-2. Orexins act as agonists on two G-protein-coupled receptors called OX 1 and OX 2 receptors. Increased wakefulness and reduced sleep is a well demonstrated response to central administration of orexin, and disruption of central orexinergic signaling leads to the sleep disorder narcolepsy in animal models and probably also in man (reviewed in Beuckmann and Yanagisawa, 2002; Kukkonen et al., 2002; Sutcliffe and de Lecea, 2002) . The other physiological roles for orexins may be regulation of energy homeostasis and stress response, probably both via central and peripheral mechanisms (reviewed in Willie et al., 2001; Beuckmann and Yanagisawa, 2002; Kirchgessner, 2002; Kukkonen et al., 2002; Smart and Jerman, 2002) .
The two orexin peptides, orexin-A and -B, are both products of the same precursor peptide, preproorexin, cleavage of which results in equimolar amounts of orexin-A and orexin-B. Orexin-A is composed of 33 amino acids and it contains two disulfide bridges, whereas orexin-B is a linear peptide of 28 residues (Sakurai et al., 1998) . Although a product of a different part of the precursor peptide, orexin-B shows a 46% sequence identity with orexin-A, and these two peptide sequences seem to have arisen through duplication of a single sequence (Alvarez and Sutcliffe, 2002 which could make orexin-B an N-terminally truncated variant of orexin-A. The secondary structure of orexin-A is not known, but orexin-B has been determined to consist of two ␣-helices in 60-to 80°angles to each other (Lee et al., 1999) . Orexin-A is much more lipophilic than orexin-B, and it is also more stable in blood and cerebrospinal fluid (Kastin and Akerstrom, 1999 ). Yet, the CNS (central nervous system) orexin-B levels are consistently 2 to 5 times higher than orexin-A levels (Mondal et al., 1999a,b; Date et al., 2000a,b) .
Orexins act as agonists on two G-protein-coupled receptors called OX 1 and OX 2 receptors. Both of these subtypes show a high (91-98%) interspecies conservation between different mammalians. Human variants of OX 1 and OX 2 receptors share a 64% sequence identity. Many studies suggest Ca 2ϩ influx as the most immediate cellular response to orexin receptor activation in different systems (van den Pol et al., 1998 (van den Pol et al., , 1999 Lund et al., 2000; Hirota et al., 2001; Kukkonen and Åkerman, 2001; Uramura et al., 2001; Holmqvist et al., 2002) . This Ca 2ϩ influx may in some systems occur via protein kinase C-dependent activation of voltage-gated Ca 2ϩ channels (van den Pol et al., 1998; Uramura et al., 2001; Xu et al., 2002 ) but a different type of Ca 2ϩ channel has been implicated in other systems (Lund et al., 2000; Kukkonen and Åkerman, 2001 ). In the CNS, the most prominent response to orexin application is an increase in synaptic activity (reviewed in Beuckmann and Yanagisawa, 2002; Kukkonen et al., 2002) . The putative role of increased Ca 2ϩ influx for this process is largely unclear (reviewed in . Orexin receptor subtypes are somewhat differentially distributed (reviewed in Willie et al., 2001; Kukkonen et al., 2002; Smart and Jerman, 2002) , but since there is yet no evidence of subtype selective signaling, it is difficult to predict the significance of this difference.
When Ca 2ϩ or inositol phosphate responses are measured in CHO (Chinese hamster ovary), PC12, or Neuro-2a cells recombinantly expressing orexin receptors, orexin-A is 10 to 100 times more potent than orexin-B on the OX 1 receptors, whereas both orexins are equipotent on the OX 2 receptors (Sakurai et al., 1998; Smart et al., 1999; Okumura et al., 2001; Holmqvist et al., 2002) . These potencies appear to be direct reflections of the binding affinities (Sakurai et al., 1998) , suggesting that despite the similarities between the orexin receptors there are interesting differences in the ligand binding domains. To further examine the parameters required for the orexin peptide-receptor interaction, we have in this study investigated the determinants of orexin-A required to activate OX 1 and OX 2 receptors. Truncated and alanine-substituted orexin-A peptides have been tested for their ability to induce Ca 2ϩ elevations in CHO-K1 cells heterologously expressing OX 1 or OX 2 receptors. The results suggest that the structures responding to orexin-A are highly conserved between OX 1 and OX 2 receptors, but also that there are some clear differences between these receptors.
Materials and Methods
Cell Culture. CHO-hOX 1 -C1 cells were produced as described in Lund et al. (2000) . CHO-hOX 2 -C1 cells were produced in a similar way; the clones used expressed receptors at approximately the same level, as determined with [ 125 I]orexin-A binding. CHO-hOX 1 -C1 and CHO-hOX 2 -C1 cells were grown in Ham's F-12 medium (Invitrogen, Carlsbad, CA) supplemented with 100 U/ml penicillin G (SigmaAldrich, St. Louis, MO), 80 U/ml streptomycin (Sigma-Aldrich), 400 g/ml geneticin (G418; Invitrogen) and 10% (v/v) fetal calf serum (Invitrogen) at 37°C in 5% CO 2 in an air-ventilated humidified incubator in 260-ml plastic culture flasks (75 cm 2 bottom area; NUNC A/S, Roskilde, Denmark). For fluorometry, the cells were grown on circular plastic culture dishes (i.d., 94 mm; NUNC A/S).
Drugs. EGTA (ethylene glycol-bis[␤-aminoethyl ether] N,N,NЈ,NЈ-tetraacetic acid) and probenecid (p-[dipropylsulfamoyl] benzoic acid) were purchased from Sigma/RBI (Natick, MA) and fura-2 acetoxymethyl ester and fluo-3 acetoxymethyl ester from Molecular Probes Inc. (Eugene, OR). Human orexin-A and -B were from Peninsula Laboratories (Merseyside, UK) or Neosystem (Strasbourg, France) and digitonin was from Merck (Darmstadt, Germany).
Peptide Synthesis. To avoid investigation of complex secondary structure changes caused by disulfide-bridge removals, we initially truncated orexin-A N-terminally to produce orexin-A 14 -33 , which is devoid of disulfide bonds, yet it has substantial activity on OX 1 and OX 2 receptors. A previous study has suggested that a significant part of the potency lost by truncation of orexin-A to orexin-A 15-33 is caused by the loss of the disulfide-bridges (Okumura et al., 2001) . All the further mutagenesis was done on orexin-A 14 -33 . We both performed a further stepwise N-terminal truncation of this peptide and one-by-one replacement of amino acids with alanine ("alanine scan") ( Table 1 ; Fig. 1 ). The truncated and alanine-scanned orexin-A peptides were synthesized using Fmoc (9-fluorenylmethoxycarbonyl) synthesis protocols with double or triple coupling reactions using TBTU (2-[H-benzotriazol-1-yl]-1,1,3,3-tetramethyluronium tetrafluoroborate) as the activator on a Symphony synthesizer (Rainin Instrument Co., Woburn, MA). Purifications were performed by reverse phase-HPLC on a ␦-Pak C 18 column (15 m; 100 Å; 25 ϫ 100 mm) (Waters, Milford, MA) using a Waters liquid chromatography system consisting of a model 600 solvent delivery pump, a Rheodine injector, and an automated gradient controller (solvent A: H 2 O-0.125% TFA [trifluoroacetic acid]; solvent B: CH 3 CN-0.1% TFA; gradient: 15% B to 60% B in 20 min). Detection was carried out using a model M2487 variable wavelength UV detector connected to the Waters Millenium software control unit. The quality control was performed by analytical reverse phase-HPLC on a Waters ␦-Pak C 18 (5 m; 100 Å; 150 ϫ 3.9 mm) column (same solvents as above; gradient: 0% B to 60% B in 20 min) using a Waters Alliance 2690 Separation Module equipped with a Waters 996 Photodiode Array Detector and by MALDI-TOF (matrix-assisted laser desorption ionization time-of-flight) mass spectrometry using a Voyager-DE instrument (Applied Biosystems, Foster City, CA).
Media. The TES-buffered medium (TBM) consisted of 137 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1.2 mM MgCl 2 , 0.44 mM KH 2 PO 4 , 4.2 mM NaHCO 3 , 10 mM glucose, 1 mM probenecid, and 20 mM 2-([2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amino) ethane sulfonic acid (TES) adjusted to pH 7.4 with NaOH. Ca 2؉ Measurements. Both the fluorescent Ca 2ϩ indicators fura-2 and fluo-3 were used to monitor changes in intracellular elevations, respectively, with high accuracy due to different K d values for Ca 2ϩ binding. The K d of 224 nM was used for fura-2, whereas the K d of 1000 nM was determined for fluo-3 in simultaneous measurement with fura-2. The low responses of the truncated C-terminal orexin-A-peptides were thus determined using fura-2, whereas all the other experiments were performed using fluo-3. It should be noted that the K d value of the indicator does not affect the relative EC 50 values or the maximum responses determined. For the experiments, the cells were harvested using phosphate-buffered saline containing 0.2 g/l EDTA, loaded with fura-2 acetoxymethyl ester or fluo-3 acetoxymethyl ester (4 M, 20 min, 37°C) in the culture medium (Ham's F-12) supplemented with 10 g/ml bovine serum albumin and 1 mM probenecid and stored on ice as pellets (medium removed). For the measurement of intracellular free calcium, one pellet was resuspended in TBM at 37°C. The fluorescence was monitored in a stirred quartz microcuvette in a thermostated cell holder of either a Hitachi F-2000 or F-4000 fluorescence spectrophotometer at the wavelengths 340 or 340/380 (excitation), 505 (emission) for fura-2 or 480 nm (excitation), 540 nm (emission) for fluo-3. Experiments were calibrated by adding 60 g/ml digitonin, which gives the maximum value of fluorescence, and 10 mM EGTA, which gives the minimum value of fluorescence. The leaked fura-2 and fluo-3 were measured in separate experiments by adding 10 mM EGTA, which chelates Ca 2ϩ bound to the extracellular indicator. ] e ) was determined as described in Lund et al. (2000) . Thus, addition of 1.5 mM EGTA in TBM gave a [Ca 2ϩ ] e of ϳ140 nM. Values are given as mean Ϯ S.E. unless otherwise indicated; N refers to the number of batches of cells on which the measurements were performed. Nonlinear curve-fitting was performed using SigmaPlot for Windows 4.01 (SPSS Science, Chicago, IL). The difference in the potency (EC 50 ) and activity (maximum response) of orexin-A and orexin-B to elevate Ca 2ϩ in 1 mM and 140 nM [Ca 2ϩ ] e (Table 2) was evaluated using Student's paired two-tailed t test. The differences in the activity (maximum response) between different peptides were evaluated using Student's nonpaired two-tailed t test.
Results
Orexin-A and -B Differentially Activate OX 1 and OX 2 Receptors. As shown previously (Lund et al., 2000; Holmqvist et al., 2001; Kukkonen and Åkerman, 2001) orexin-A caused large elevations in intracellular [Ca 2ϩ ] in OX 1 receptor-expressing CHO-K1 cells (Table 2) . Orexin-B was 7-fold less potent (Tables 2 and 3 ; Fig. 2A) . No difference in the potency between the ligands was seen for the OX 2 receptor (Tables 2 and 3 ; Fig. 2B ). We have previously shown that OX 1 -mediated Ca 2ϩ response to low concentrations of orexin-A requires extracellular Ca 2ϩ in CHO cells (Lund et al., 2000; Holmqvist et al., 2001; Kukkonen and Åkerman, 2001 ). This is not specific for orexin-A because an external Ca 2ϩ dependence was also seen with respect to both orexin-A and -B response with both OX 1 and OX 2 receptors (Table 2 ; Fig. 2 ). Reduction in extracellular Ca 2ϩ caused a considerable increase in the n H value for all combinations of ligand/ receptor. This change was largest for the effect of orexin-B on the OX 2 receptor.
With each batch of cells, concentration-response relationships were determined with both orexin-A and orexin-B in normal (1 mM) and low (140 nM) extracellular Ca 2ϩ . This allows comparison within individual batches of cells and the slight variance between the batches of cells does not distort the results. From these data the significance of any difference between high and low extracellular Ca 2ϩ and orexin-A and orexin-B was calculated using the paired t test (Table 3) . These data confirm the fact that there is a difference in the potency between orexin-A and -B for the OX 1 receptor but not for the OX 2 receptor. Orexin-B appears to give a slightly (10 -24%) lower maximum response than orexin-A in all the cases. A right-shift in the EC 50 values of both orexin-A and -B is seen upon reduction of extracellular Ca 2ϩ , but the maximum responses appear unaffected. Notably, the shift appears lower for orexin-B than for orexin-A with both OX 1 and OX 2 receptors.
C-Terminal Orexin-A Peptides Are Agonistic for the OX 1 and OX 2 Receptors. C-Terminal truncation of orexin-A to orexin-A 14 -33 (Fig. 1) increased the EC 50 to 27 nM from 4 nM (OX 1 ) or 7 nM (OX 2 ) (Tables 4 and 5). The The data from the same experiments as in Table 3 were normalized to the response to orexin-A in 1 mM ͓Ca 2ϩ ͔ e in each batch of cells. 
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at ASPET Journals on July 12, 2017 jpet.aspetjournals.org Downloaded from maximum response, however, was not affected as calculated using the nonpaired t test. The effect of a further reduction in the peptide length is shown in Fig. 3 . The response to 100 nM peptide fell when the peptide length was reduced to 18 amino acids (orexin-A 16 -33 ) (Fig. 3,A and B) . Further truncation to 15 amino acids (orexin-A 19 -33 ) completely abolished the Ca 2ϩ response to 100 nM peptide (Fig. 3, A and B) . In a similar manner, both OX 1 -and OX 2 -expressing cells ceased respond- ing to 1 M peptide when its length was reduced to 12 amino acids (orexin-A 22-33 ), although the response to 10 M peptide was retained (Fig. 3, A and B) . With further truncation the fall in activity was eminent in the OX 1 -expressing cells, and the C-terminal decapeptide (orexin-A 24 -33 ) gave no response even at the concentration of 10 M. The decline in activity with reduced peptide length was markedly lower with OX 2 -receptors. At 10 M, the nonapeptide (orexin-A 25-33 ) gave a robust response, and a slight response was still observed with the heptapeptide (orexin-A 27-33 ) but not with the hexapeptide (orexin-A 28 -33 ) (Fig. 3, A and B) .
To evaluate the role of individual amino acid residues in the C-terminal orexin-A peptide for the binding and activation of the orexin receptors, we performed an alanine-scan of the residues 14 -26 in the orexin-A 14 -33 (Table 1) . Similar areas/residues of importance in orexin-A were observed both for OX 1 and OX 2 receptors. Replacements of Arg15, Leu16, or Tyr17 with alanine caused a 2-fold reduction in the potency of the peptide (Tables 4 and 5; Fig. 4) . The OX 1 receptor may be less sensitive to the mutation of Tyr17 than the OX 2 receptor. A more dramatic reduction in the potency was seen with mutation of Leu20 to alanine: the potency for the OX 1 receptor was reduced 25-fold and the potency for the OX 2 receptor 11-fold (Tables 4 and 5; Figs. 4 and 5A). Remarkably, neither the mutation of the Leu19 nor His21 markedly affected the potency of the peptide (Tables 4 and 5; Figs. 4 and 5B). Mutation of Asn25 and His26 to alanine caused a progressive reduction in the potency, which was more pronounced for the OX 1 receptor (Tables 4 and 5 ; Figs. 4 and 5C) . Thus, the results with OX 1 and OX 2 receptors are largely similar, except for differences with some mutations (Tyr17Ala, Leu20Ala, Asn25Ala, His26Ala).
Some of the peptides, as also orexin-A, display high slope factors (n H ) (Tables 4 and 5; Fig. 5B) . We have previously shown that Ca 2ϩ influx can amplify the phospholipase C response at low concentrations of orexin-A in CHO-OX 1 cells (Lund et al., 2000) . Therefore, different slope factors could indicate different degrees of synergism between the two signals to phospholipase C, and thus a differential ability to activate Ca 2ϩ influx and Ca 2ϩ release responses. We therefore tested the ability of chosen peptides to elevate intracellular Ca 2ϩ in low (140 nM) extracellular [Ca 2ϩ ]. The potency of orexin-A was shifted 10-to 14-fold to the right and the potency of orexin-B somewhat less (6-fold) by the reduction of extracellular [Ca 2ϩ ] (Fig. 6 ). Orexin-A 14 -33 was affected to a similar degree as orexin-A (11-fold shift; Fig. 6 ). In contrast, orexin-A 14 -33 R15A was much less affected (4-to 5-fold shift), even less than orexin-B. However, the reduction in potency for orexin-A 14 -33 L16A, -Y17A, and -H21A was much larger (18-to 67-fold), especially in the case of the OX 1 receptor. However, the difference in the shift of the EC 50 did not correlate with the slope factor. Note that the determination of the EC 50 for orexin-A 14 -33 L20A in the low extracellular Ca 2ϩ was impossible due to its low potency. We wanted to further confirm that the reduced potency of the mutated/truncated orexin peptides was due to reduced affinity for the orexin receptor. There is no pharmacologically satisfactory binding assay for orexin receptors; at the moment, orexin receptor binding has to be conducted using radio-or fluorescently labeled orexin-A (an agonist) and intact cells (Kane et al., 2000; Darker et al., 2001; Holmqvist et al., 2001; Smart et al., 2001) . Therefore, an alternative qualitative approach was used. For this the cells were exposed to a slightly lower concentration of the peptides than required to give a minimum detectable Ca 2ϩ response. After a 2-min preincubation, orexin-A or orexin-A 14 -33 at different concentrations was added. Neither orexin-A nor any of the peptides inhibited subsequent response to orexin-A or orexin-A 14 -33 , confirming that the reduced potency of the peptides was indeed due to reduced affinity. It should be noted that this approach cannot give an assumption of how much the affinity is reduced, only that the binding affinity is not higher than the EC 50 .
Discussion
In the present study we have investigated the differences between OX 1 and OX 2 receptors with respect to the specificity of activation by modified orexin peptides. The results obtained in this study indicate that both OX 1 and OX 2 receptors require very similar determinants from orexin-A to allow binding to and activation of the receptor, which indicates that analogous domains of OX 1 and OX 2 receptors interact with orexin-A. However, some interesting differences are seen, the most obvious of which being the less strict requirements of the OX 2 receptor for ligand binding.
As also previously shown, orexin-B had potency equal to orexin-A for the OX 2 receptor, but 10-to 100-fold lower relative potency for the OX 1 receptor. Thus, the OX 2 receptor cannot distinguish between orexin-A and -B as the OX 1 receptor does. The OX 1 receptor was much more affected by the N-terminal truncation of orexin-A than the OX 2 receptor. The first truncation of orexin-A to orexin-A 14 -33 , which removes the sulfhydryl bridges, essentially abolished the difference between OX 1 and OX 2 receptors with respect to orexin-A. Since orexin-B is N-terminally more or less truncated as compared with orexin-A, these data from the truncation of orexin-A may in part explain why orexin-B is as potent as orexin-A on the OX 2 receptor. However, domains interacting with the most N-terminal portion of orexin-A are not the only difference between the two receptors, as the OX 2 receptor also resisted further truncation far better than the jpet.aspetjournals.org OX 1 receptor. Alanine-scan identified residues of particular importance for orexin receptor activation. These residues were the same with respect to the activation of both OX 1 and OX 2 receptors, but the potency for the OX 2 receptor was less markedly affected. This further supports the notion of less strict requirements for binding and activation of the OX 2 receptor. Human OX 1 and OX 2 display 64% overall sequence identity (Sakurai et al., 1998 ). An even higher degree of identity and similarity are found between the proximal N termini and the extracellular loop 1 of the receptors. This might suggest that these parts of the receptors are important for the orexin binding, as is also suggested by the almost complete loss of orexin binding caused by the Glu54Lys (position homologous to Glu54 in human OX 2 receptor) mutation in the canine OX 2 receptor (Hungs et al., 2001) . No obvious differences, which could explain the different behavior of OX 1 and OX 2 receptor, are seen.
All the peptides displayed slope factors above one and in addition, many of the truncated and alanine-scanned peptides, although not orexin-A itself, displayed slope factors (n H ) above 2.5. This may suggest cooperative binding, which in the case of G-protein-coupled receptors would indicate formation/presence of receptor di/oligomers. However, this has not been seen in binding studies (Sakurai et al., 1998; T. Holmqvist, K. E. O. Åkerman, J. P. Kukkonen, unpublished data) , but the unsatisfactory conditions for the binding assay (see under Results) may mask this. Apparent cooperativity could also originate from the functional level. We have previously reported that orexin-A activates Ca 2ϩ influx as a primary response mechanism. Ca 2ϩ influx and an unknown signal from the receptor act synergistically to activate phospholipase C, since no phospholipase C activation is seen with Ca 2ϩ influx alone, and in the absence of Ca 2ϩ influx phospholipase C is activated only at 100ϫ higher concentration of orexin-A (Lund et al., 2000; Kukkonen and Åkerman, 2001) . We hypothesized that the reduced ability of some of the peptides to activate one of the Ca 2ϩ responses, influx or release, could explain the high slope factors. Our experiments indeed confirmed that there are clear differences in the relative potencies between different mutant peptides toward these responses. The Ca 2ϩ responses mediated by the OX 2 receptor were for most of the peptides less affected by removal of extracellular Ca 2ϩ than the responses via OX 1 receptor. However, these differences do not explain the apparent cooperativity, and other explanations may be required. [Ca 2ϩ ] e . In A, the Leu20 to Ala mutation shifts the concentration response curve of orexin-A 14 -33 15-to 35-fold to the right. In B, the His21Ala mutation results in peptides with apparent highly cooperative response (steep concentration-response curves). Leu20Ala (A) and His26Ala (C) mutations show that the OX 1 receptor is more sensitive to the orexin-A mutations than the OX 2 receptor. N ϭ 9. It has been shown before that N-terminal truncation of orexin-A to orexin-A 15-33 (19 amino acids), which completely eliminates all cysteines, reduces the potency for the OX 1 receptor 60-to 170-fold (Darker et al., 2001; Okumura et al., 2001 ) but the reduction is only 20-fold for the OX 2 receptor (Okumura et al., 2001) . In the present study the potency of orexin-A was decreased only 7-and 4-fold, respectively, for the OX 1 and OX 2 receptors upon truncation to orexin-A 14 -33 . Darker et al. (2001) have characterized the effect of further truncation of orexin-A on the activation of the OX 1 receptor: truncation of orexin-A to 19, 17, 16, 15, 10, and 5 amino acids progressively reduced the response to 10 M peptide, and 5 and 10 amino acid-long peptides were inactive. In contrast to this, we did not observe any significant reduction in the maximum response until the chain length was reduced to 12 or 11 amino acids. In the present study, the shortened chain instead decreased the potency (increased the EC 50 ). This apparent discrepancy could be caused by a somewhat higher expression level in our CHO cells than those used in Darker et al. (2001) . In our CHO cells the EC 50 value for orexin-A is Ͼ10-fold lower than the binding affinity for OX 1 receptors (T. Holmqvist, K. E. O. Åkerman, J. P. Kukkonen, unpublished data) as compared with only a 6-fold difference in Darker et al. (2001) . Darker et al. (2001) have also shown that truncation of orexin-A to orexin-A 15-33 abolishes this difference in the EC 50 and binding affinity; thus, this truncation may decrease both the binding affinity and the efficacy of the peptide. Our semiquantitative estimation of the binding affinity suggests that further truncation may only reduce the binding affinity, and not the efficacy. In other words, once bound, both orexin-A 14 -33 and the shorter peptides may have a similar ability to activate the receptor. The most C-terminal amino acids may be the most important for the activation of the receptor, whereas the additional N-terminal amino acids may increase the binding affinity and efficacy by making contact with the receptor and stabilizing orexin-A structure. The importance of the C terminus is evident since this area is highly conserved between orexin-A and orexin-B (Fig.  1) . The present results support the view that for this kind of study, high receptor expression levels are useful.
Alanine-scan of residues 14 to 26 in orexin-A 14 -33 identified three areas of interest, which were the same in both OX 1 and OX 2 receptors: amino acids 15 to 17, 20, and 25 to 26. Alanine-scan of orexin-A 15-33 was performed in Darker et al. (2001) with results similar to the results in the present study with respect to OX 1 receptor activation. This study also showed that the receptor response is extremely sensitive to mutations in the outermost C terminus (amino acids 26 -33), as can be expected from the highly similar C termini of orexin-A and -B. In contrast to Darker et al. (2001) , we failed to detect any decrease in the potency by mutation of residues 21 to 24. Neither we nor Darker et al. (2001) detected any mutation that would markedly increase the potency of the peptide. The most interesting mutation is the Leu20Ala, which causes an over 10-fold drop in the potency of the orexin-A 14 -33 . In contrast to the findings of Darker et al. (2001) we saw almost no effect of the mutation of the adjacent amino acids, Leu19 or His21. Mutation of a leucine to alanine does not cause any change in the charge of the peptide; neither can the effect be explained by steric hindrance, which should instead be diminished by the less bulky alanine. Therefore, the effect of this mutation is likely to affect the secondary or tertiary structure of orexin-A 14 -33 rather than the interaction with the orexin-binding site. If orexin-A, as orexin-B (Lee et al., 1999) forms an ␣-helical structure in this region, then replacement of leucine with alanine should also not have any remarkable effect on the secondary structure. Since the three-dimensional structure of orexin-A is unknown, no conclusion of its structure and the effects of mutations thereon can be made. The alanine-scanned peptides activated the OX 2 receptor with potencies very similar to those for the OX 1 receptor. However, the OX 2 receptor once again proved less "fussy" in its requirements on the orexin-A 15-33 peptide than the OX 1 receptor.
Orexin receptor subtypes are somewhat differentially expressed in the CNS and in the periphery, but the significance of this is unknown since no separate cellular functions have been ascribed to the receptor subtypes, and the relative amounts of orexin-A versus orexin-B seem rather constant in the different CNS areas . Therefore, some of the major issues are whether orexin receptor subtypes can couple to different signaling pathways and whether different orexin peptides can cause "signal-trafficking" (Kenakin, 1995) even via a single receptor subtype. The data from the experiments with reduced extracellular [Ca 2ϩ ] suggest that orexin peptides may have an inherent ability to do this. Also, some in vivo and in vitro data suggest that orexin-B is more efficacious than orexin-A (see , which is unexplainable based on the recombinant pharmacology. We propose that the physiological roles of orexins can only be elucidated in the light of much further data on the receptor subtype specificity in ligand binding and signaling pathway activation.
